Exegenesis Bio is a clinical-stage global cell and gene therapy company that operates in Philadelphia, Boston, China, and Singapore. Founded in 2019 with strong financial backing, the company has built a broad pipeline of innovative genetic medicines and fully integrated manufacturing capabilities. The company is advancing an early to clinical-stage gene therapy pipeline with three initial focused therapeutic areas: CNS, ophthalmology, and Liver. The company’s vision is to develop and increase access to gene and cell therapies for patients around the world! Founded in 2019 with strong financial backing, Exegenesis Bio has developed a rich pipeline of early to clinical stage programs in eye, CNS and liver-directed genetic diseases. The company is building fully integrated, research, development and manufacturing capabilities to support its programs at commercial scale. Exegenesis Bio has recruited a globally experienced management team with extensive experience in building and scaling biotechnology and gene therapy companies. The company has raised over $120 M since beginning operations in 2019 and is now expanding operations to Philadelphia, Boston and Singapore. Exegenesis Bio expects to dose the first patient with its next generation AAV gene therapy for Type 1 Spinal Muscular Atrophy (SMA) this year. The company plans to file two Global INDs in 2022. Website: https://www.exegenesisbio.com/ Contacts: Company Information: Contact@ExegenesisBio.com Business Development: BD@ExegenesisBio.com Careers: Careers@ExegenesisBio.com